Maternal serum thrombospondin‐4 levels in placenta accreta spectrum: A case–control study
International Journal of Gynecology & Obstetrics · 2026
DOI: 10.1002/ijgo.71191 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Kubilay Çanga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Perinatology, Department of Obstetrics and Gynecology, Etlik City Hospital, Ankara, Türkiye. Hauptthemen laut MEDLINE: Placenta Accreta, Thrombospondins. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
This study evaluates maternal serum thrombospondin‐4 (TSP‐4) levels in pregnancies complicated by placenta accreta spectrum (PAS) and examine their association with maternal and neonatal outcomes.
Methods
This prospective case–control study included 80 pregnancies, comprising 40 cases with PAS and 40 healthy controls. The study was conducted at Ankara Etlik City Hospital between June 2025 and March 2026. Maternal serum TSP‐4 levels were measured by ELISA. Clinical, obstetric, maternal, and neonatal data were recorded. Univariable and multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed, including comparison of a clinical model with and without TSP‐4.
Results
Maternal serum TSP‐4 levels were significantly higher in the PAS group than in controls (9.88 [9.38–10.00] vs. 7.83 [6.01–9.30] ng/mL; P < 0.001). PAS was associated with prolonged hospitalization, increased transfusion requirement, earlier delivery, lower birth weight, lower Apgar scores, higher neonatal intensive care unit admission rates, and increased rates of adverse maternal and neonatal composite outcomes. Within the PAS cohort, TSP‐4 levels were not associated with composite adverse maternal outcome, PAS grade, or major neonatal outcomes. In multivariable analysis, TSP‐4 was the only variable independently associated with PAS (adjusted odds ratio 1.863, 95% confidnece interval [CI] 1.308–2.651; P = 0.001). ROC analysis demonstrated moderate discriminative ability (area under the curve [AUC] 0.796, 95% CI 0.697–0.895). At a cutoff value of >9.47 ng/mL, sensitivity and specificity were 72.5% and 82.5%, respectively, yielding a positive likelihood ratio of 4.14 and a negative likelihood ratio of 0.33. Adding TSP‐4 to the clinical model increased the AUC from 0.660 to 0.816 ( P = 0.002 for the difference).
Conclusion
Maternal serum TSP‐4 is elevated in PAS and, by adding discriminative value to clinical predictors, might be considered a complementary biomarker candidate for antenatal risk stratification, although these associations warrant confirmation in larger, prospective, multicenter cohorts. Its value appears greater for identifying disease presence than for reflecting disease severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Perinatology, Department of Obstetrics and Gynecology, Etlik City Hospital, Ankara, Türkiye.
ORCID-Profile: Kubilay Çanga
Zitieren
APA
Çanga, K., Öztürk, Ö., Bahadir, İ. B., Elüstü, B., Özcan, Ü., & Yilmaz, Z. V. (2026). Maternal serum thrombospondin‐4 levels in placenta accreta spectrum: A case–control study. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.71191
Vancouver
Çanga K, Öztürk Ö, Bahadir İB, Elüstü B, Özcan Ü, Yilmaz ZV. Maternal serum thrombospondin‐4 levels in placenta accreta spectrum: A case–control study. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.71191
BibTeX
@article{anga2026,
author = {Çanga, Kubilay and Öztürk, Özge and Bahadir, İbrahim Buğra and Elüstü, Bengisu and Özcan, Ümran and Yilmaz, Zehra Vural},
title = {Maternal serum thrombospondin‐4 levels in placenta accreta spectrum: A case–control study},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
doi = {10.1002/ijgo.71191}
}
EUVIMED